This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is McKesson (MCK) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
Zacks.com featured highlights include Agnico Eagle Mines, NetEase, Qifu Technology, UGI and McKesson
by Zacks Equity Research
AEM, NTES, QFIN, UGI, and MCK stand out as top dividend growth picks for navigating the second half of 2025 with stability and upside.
5 Top-Ranked Dividend Growth Stock Picks for the Second Half of 2025
by Sweta Killa
AEM, NTES, QFIN, UGI and MCK stand out as strong dividend growth picks for steady income and upside in 2H25.
WST Stock Builds on GLP-1 Growth, Annex 1 and Margins in Focus
by Zacks Equity Research
West Pharmaceutical Services rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
4 Stocks With Solid Shareholder Yield to Safeguard Your Portfolio
by Indrajit Bandyopadhyay
MCK, LRCX, CTSH, and RITM stand out with strong shareholder yield, blending income, buybacks and debt reduction for portfolio defense.
Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.
Cardinal Health, Inc. (CAH) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why McKesson (MCK) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why McKesson (MCK) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson (MCK) Rises Higher Than Market: Key Facts
by Zacks Equity Research
McKesson (MCK) concluded the recent trading session at $730.80, signifying a +1.82% move from its prior day's close.
Investors Heavily Search McKesson Corporation (MCK): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is McKesson (MCK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why McKesson (MCK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why McKesson (MCK) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here is What to Know Beyond Why McKesson Corporation (MCK) is a Trending Stock
by Zacks Equity Research
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
MCK vs. CAH: Which Drug Distribution Giant Has the Healthier Outlook?
by Indrajit Bandyopadhyay
Both McKesson and Cardinal Health dominate drug distribution, but which stock offers better growth and stability in 2025? Here we discuss which company has better long-term potential.
Is McKesson (MCK) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), McKesson (MCK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Cooper Companies Q2 Earnings Likely to Reflect Seasonal Trends
by Zacks Equity Research
COO's fiscal second-quarter results are expected to follow seasonal trends, with a lighter start compared to the previous two reported quarters.
MCK Stock Gains More Than 4% Following Strong Q4: Should You Buy Now?
by Indrajit Bandyopadhyay
McKesson's strong fundamentals are likely to keep it ahead of the competition. Should investors add it to their portfolio now?
3 Reasons Growth Investors Will Love McKesson (MCK)
by Zacks Equity Research
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.